Bevacizumab in recurrent malignant glioma

被引:5
作者
Lauren E. Abrey
机构
关键词
Irinotecan; Recurrent Malignant Glioma; Recurrent High Grade Glioma; Normalize Tumor Vasculature; Decrease Contrast Enhancement;
D O I
10.1007/s11910-008-0035-9
中图分类号
学科分类号
摘要
引用
收藏
页码:233 / 234
页数:1
相关论文
共 15 条
[1]  
Vredenburgh J.J.(2007)Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 4722-4729
[2]  
Desjardins A.(2007)Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization Clin Cancer Res 13 3395-3402
[3]  
Herndon J.E.(2007)A pilot study of bevacizumab and stereotactic intensity modulated re-irradiation for recurrent high grade gliomas. ASCO Annual Meeting Proceedings Part I J Clin Oncol 25 2028-95
[4]  
Dings R.P.(2007)AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 83-4721
[5]  
Loren M.(2007)Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study J Clin Oncol 25 4714-undefined
[6]  
Heun H.(undefined)undefined undefined undefined undefined-undefined
[7]  
Mohile N.A.(undefined)undefined undefined undefined undefined-undefined
[8]  
Abrey L.E.(undefined)undefined undefined undefined undefined-undefined
[9]  
Lymberis S.C.(undefined)undefined undefined undefined undefined-undefined
[10]  
Batchelor T.T.(undefined)undefined undefined undefined undefined-undefined